A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05067140
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved sy – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Arvinas Androgen Receptor, Inc.
Acronym:

Pin It on Pinterest